Study reveals how eye damage tracks with vision decline in dry AMD
NCT ID NCT07424235
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study examined how vision loss progresses in people with geographic atrophy, an advanced form of dry age-related macular degeneration. Researchers analyzed past medical records and eye images from 60 patients to see which retinal changes are linked to faster vision decline. No treatments were tested—the goal was simply to better understand the disease's natural history.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
60 people
The number who actually took part.
- Started
-
Jan 2015
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population consists of patients aged 50 years or older with geographic atrophy secondary to dry age-related macular degeneration, identified retrospectively from a single tertiary referral center. The analysis includes eyes meeting predefined anatomical and functional criteria similar to those used in recent clinical trials, based on clinical records and retinal imaging collected during routine care.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female patients aged 50 years or older at baseline. * Diagnosis of geographic atrophy secondary to dry age-related macular degeneration in the study eye. * Well-demarcated geographic atrophy lesions confirmed by fundus autofluorescence imaging, with a total lesion area between 2.5 mm² and 17.5 mm². * Presence of hyperautofluorescence in the junctional zone of the geographic atrophy lesion. * Best-corrected visual acuity between 45 and 83 ETDRS letters at baseline. * Availability of longitudinal clinical and imaging data with at least 6 months of follow-up. Exclusion Criteria: * Evidence or history of neovascular (wet) age-related macular degeneration in the study eye. * Prior intravitreal therapy or systemic treatments specifically targeting age-related macular degeneration. * Geographic atrophy lesions contiguous with peripapillary atrophy. * Coexisting ocular diseases that could independently affect visual acuity or retinal structure. * Incomplete or poor-quality clinical or imaging data precluding reliable assessment of study outcomes.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could years of eye injections weigh down the upper eyelid?
- Can blocking rogue immune cells stop a leading cause of blindness?
- Can a new eye injection protect vision in geographic atrophy?
- Can genetics predict the worsening of geographic atrophy?
- A window into the eye: could functional tests predict macular degeneration progression?
- Can a VR maze reveal hidden vision loss in macular degeneration?